Though new targeted therapies for colorectal cancer, which progresses from local intestinal tumors to metastatic disease, are being developed, tumor specificity remains an important problem, and side effects a major concern. Here, we show that the protein-fatty acid complex BAMLET (bovine alpha-lactalbumin made lethal to tumor cells) can act as a peroral treatment for colorectal cancer. ApcMin/+ mice, which carry mutations relevant to hereditary and sporadic human colorectal cancer, that received BAMLET in the drinking water showed long-term protection against tumor development and decreased expression of tumor growth-, migration-, metastasis- and angiogenesis-related genes. BAMLET treatment via drinking water inhibited the Wnt/β-catenin and PD-1 signaling pathways and prolonged survival without evidence of toxicity. Systemic disease in the lungs, livers, spleens, and kidneys, which accompanied tumor progression, was inhibited by BAMLET treatment. The metabolic response to BAMLET included carbohydrate and lipid metabolism, which were inhibited in tumor prone ApcMin/+ mice and weakly regulated in C57BL/6 mice, suggesting potential health benefits of peroral BAMLET administration in addition to the potent antitumor effects. Together, these findings suggest that BAMLET administration in the drinking water maintains antitumor pressure by removing emergent cancer cells and reprogramming gene expression in intestinal and extra-intestinal tissues.

Department of Pathology and Molecular Medicine Motol University Hospital 2nd Faculty of Medicine Charles University Praha 150 06 Prague Czech Republic

Division of Microbiology Immunology and Glycobiology Department of Laboratory Medicine Faculty of Medicine Lund University Klinikgatan 28 221 84 Lund Sweden

See more in PubMed

Abbas Z, Rehman S. An overview of cancer treatment modalities. Neoplasm. 2018;1:139–157.

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

Jasperson, K. W., Patel, S. G. & Ahnen, D. J. APC-associated polyposis conditions. GeneReviews®[Internet] (2017).

Vogelstein B, et al. Genetic alterations during colorectal-tumor development. New Engl. J. Med. 1988;319:525–532. doi: 10.1056/NEJM198809013190901. PubMed DOI

McCart AE, Vickaryous NK, Silver A. Apc mice: Models, modifiers and mutants. Pathol.-Res. Pract. 2008;204:479–490. doi: 10.1016/j.prp.2008.03.004. PubMed DOI

Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990;247:322–324. doi: 10.1126/science.2296722. PubMed DOI

The Jackson Laboratory. C57BL/6J-ApcMin/J. https://www.jax.org/strain/002020 (2023).

Mok KH, Nagashima T, Day IJ, Hore P, Dobson CM. Multiple subsets of side-chain packing in partially folded states of α-lactalbumins. Proc. Natl. Acad. Sci. 2005;102:8899–8904. doi: 10.1073/pnas.0500661102. PubMed DOI PMC

Pettersson J, Mossberg A-K, Svanborg C. α-Lactalbumin species variation, HAMLET formation, and tumor cell death. Biochem. Biophys. Res. Commun. 2006;345:260–270. doi: 10.1016/j.bbrc.2006.04.081. PubMed DOI

Rammer P, et al. BAMLET activates a lysosomal cell death program in cancer cells. Mol Cancer Therap. 2010;9:24–32. doi: 10.1158/1535-7163.Mct-09-0559. PubMed DOI

Brinkmann CR, Heegaard CW, Petersen TE, Jensenius JC, Thiel S. The toxicity of bovine α-lactalbumin made lethal to tumor cells is highly dependent on oleic acid and induces killing in cancer cell lines and noncancer-derived primary cells. FEBS J. 2011;278:1955–1967. doi: 10.1111/j.1742-4658.2011.08112.x. PubMed DOI

Zhong S, et al. Cytotoxicity and apoptosis induction of bovine alpha-lactalbumin-oleic acid complex in human breast cancer cells. Food Sci. Technol. Res. 2015;21:103–110. doi: 10.3136/fstr.21.103. DOI

Mahanta S, Paul S. Stable self-assembly of bovine α-lactalbumin exhibits target-specific antiproliferative activity in multiple cancer cells. ACS Appl. Mater. Interfaces. 2015;7:28177–28187. doi: 10.1021/acsami.5b06076. PubMed DOI

Sinevici N, et al. The novel therapeutic potential of bovine α-lactalbumin made lethal to tumour cells (BALMET) and oleic acid in oral squamous cell carcinoma (OSCC) Eur. J. Cancer Prev. 2021;30:178–187. doi: 10.1097/CEJ.0000000000000617. PubMed DOI

HåkanssoN A, Zhivotovsky B, Orrenius S, Sabrarwal H, Svanborg C. Apoptosis induced by a human milk protein. Proc. Natl. Acad. Sci. 1995;92:8064–8068. doi: 10.1073/pnas.92.17.8064. PubMed DOI PMC

Pettersson-Kastberg J, et al. α-Lactalbumin, engineered to be nonnative and inactive, kills tumor cells when in complex with oleic acid: A new biological function resulting from partial unfolding. J. Mol. Biol. 2009;394:994–1010. doi: 10.1016/j.jmb.2009.09.026. PubMed DOI

Svensson M, Håkansson A, Mossberg A-K, Linse S, Svanborg C. Conversion of α-lactalbumin to a protein inducing apoptosis. Proc. Natl. Acad. Sci. 2000;97:4221–4226. doi: 10.1073/pnas.97.8.4221. PubMed DOI PMC

Duringer C, Hamiche A, Gustafsson L, Kimura H, Svanborg C. HAMLET interacts with histones and chromatin in tumor cell nuclei. J. Biol. Chem. 2003;278:42131–42135. doi: 10.1074/jbc.M306462200. PubMed DOI

Svensson M, et al. α-Lactalbumin unfolding is not sufficient to cause apoptosis, but is required for the conversion to HAMLET (human α-lactalbumin made lethal to tumor cells) Prot. Sci. 2003;12:2794–2804. doi: 10.1110/ps.0231003. PubMed DOI PMC

Gustafsson L, Leijonhufvud I, Aronsson A, Mossberg A-K, Svanborg C. Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid. New Engl. J. Med. 2004;350:2663–2672. doi: 10.1056/NEJMoa032454. PubMed DOI

Fischer W, et al. Human α-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res. 2004;64:2105–2112. doi: 10.1158/0008-5472.CAN-03-2661. PubMed DOI

Mossberg AK, Wullt B, Gustafsson L, Månsson W, Ljunggren E, Svanborg C. Bladder cancers respond to intravesical instillation of (HAMLET human α-lactalbumin made lethal to tumor cells) Int. J. Cancer. 2007;121:1352–1359. doi: 10.1002/ijc.22810. PubMed DOI

Mossberg A-K, Hou Y, Svensson M, Holmqvist B, Svanborg C. HAMLET treatment delays bladder cancer development. J. Urol. 2010;183:1590–1597. doi: 10.1016/j.juro.2009.12.008. PubMed DOI

Puthia M, Storm P, Nadeem A, Hsiung S, Svanborg C. Prevention and treatment of colon cancer by peroral administration of HAMLET (human α-lactalbumin made lethal to tumour cells) Gut. 2014;63:131–142. doi: 10.1136/gutjnl-2012-303715. PubMed DOI PMC

Brisuda A, et al. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex. Nat. Commun. 2021;12:1–16. doi: 10.1038/s41467-021-23748-y. PubMed DOI PMC

Su L-K, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992;256:668–670. doi: 10.1126/science.1350108. PubMed DOI

Stenhouse G, Fyfe N, King G, Chapman A, Kerr K. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J. Clin. Pathol. 2004;57:383–387. doi: 10.1136/jcp.2003.007138. PubMed DOI PMC

Hien TT, et al. Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy. Int. J. Cancer. 2023;1:1. PubMed

Hansen JS, et al. Peptide–oleate complexescreate novel membrane-bound compartments. Mol. Biol. Evol. 2020;37:3083–3093. doi: 10.1093/molbev/msaa138. PubMed DOI

Brest P, et al. Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET. Cancer research. 2007;67:11327–11334. doi: 10.1158/0008-5472.CAN-07-1153. PubMed DOI

Storm P, et al. Conserved features of cancer cells define their sensitivity to HAMLET-induced death; c-Myc and glycolysis. Oncogene. 2011;30:4765–4779. doi: 10.1038/onc.2011.196. PubMed DOI PMC

Halberg RB, et al. Long-lived Min mice develop advanced intestinal cancers through a genetically conservative pathway. Cancer Res. 2009;69:5768–5775. doi: 10.1158/0008-5472.CAN-09-0446. PubMed DOI PMC

Königshoff M, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PloS One. 2008;3:e2142. doi: 10.1371/journal.pone.0002142. PubMed DOI PMC

Wong RP, Hwang WS, Field SK. Familial adenomatous polyposis and lung cancer. J. Surg. Oncol. 1995;60:213–214. doi: 10.1002/jso.2930600314. PubMed DOI

Yamaguchi M, Takai S. Chronic Administration of bovine milk-derived α-lactalbumin improves glucose tolerance via enhancement of adiponectin in goto–kakizaki rats with type 2 diabetes. Biol. Pharm. Bull. 2014;37:404–408. doi: 10.1248/bpb.b13-00762. PubMed DOI

Gao J, Song J, Du M, Mao X. Bovine α-lactalbumin hydrolysates (α-LAH) ameliorate adipose insulin resistance and inflammation in high-fat diet-fed C57BL/6J mice. Nutrients. 2018;10:242. doi: 10.3390/nu10020242. PubMed DOI PMC

Boscaini S, Cabrera-Rubio R, Speakman JR, Cotter PD, Cryan JF, Nilaweera KN. Dietary α-lactalbumin alters energy balance, gut microbiota composition and intestinal nutrient transporter expression in high-fat diet-fed mice. Br. J. Nutrit. 2019;121:1097–1107. doi: 10.1017/S0007114519000461. PubMed DOI

Brahmer JR, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. New Engl. J. Med. 2012;366:2455–2465. doi: 10.1056/NEJMoa1200694. PubMed DOI PMC

Hu H, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 2022;7:38–48. doi: 10.1016/S2468-1253(21)00348-4. PubMed DOI

Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl. J. Med. 2015;372:2509–2520. doi: 10.1056/NEJMoa1500596. PubMed DOI PMC

Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci. Adv. 2020;6:ea2712. doi: 10.1126/sciadv.abd2712. PubMed DOI PMC

Stacey A, et al. Lactation is disrupted by alpha-lactalbumin deficiency and can be restored by human alpha-lactalbumin gene replacement in mice. Proc. Natl. Acad. Sci. 1995;92:2835–2839. doi: 10.1073/pnas.92.7.2835. PubMed DOI PMC

Wijesinha-Bettoni R, Dobson CM, Redfield C. Comparison of the structural and dynamical properties of holo and apo bovine α-lactalbumin by NMR spectroscopy. J. Mol. Biol. 2001;307:885–898. doi: 10.1006/jmbi.2001.4530. PubMed DOI

Krämer A, Green J, Pollard J, Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523–530. doi: 10.1093/bioinformatics/btt703. PubMed DOI PMC